Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on chondrosarcomas.

Warren A Chow1

  • 1City of Hope Medical Center, Division of Medical Oncology & Therapeutics Research, Duarte, CA 91010, USA. wchow@coh.org

Current Opinion in Oncology
|June 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Evolving Landscape of Systemic Therapy for Liposarcoma.

Cancers·2026
Same author

Assessment of real-world surveillance strategies for patients undergoing systemic therapy for brain metastases.

Frontiers in oncology·2026
Same author

Associations Between Pre-Existing Cardiovascular Disease and Survival in Patients on Immune Checkpoint Inhibitor Therapy.

Cancer medicine·2025
Same author

Complete remission of locoregionally metastatic melanoma after one single dose of pembrolizumab: A case report.

JAAD case reports·2025
Same author

Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy.

Cancers·2025
Same author

Single protein encapsulated SN38 for tumor-targeting treatment.

Journal of translational medicine·2023
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Recent advances in understanding chondrosarcomas, including molecular diagnostics and therapeutics, offer improved classification and treatment strategies for these heterogeneous tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chondrosarcomas are a heterogeneous group of bone and soft tissue tumors.
  • Prognosis traditionally correlates with histologic grade and surgical adequacy.

Purpose of the Study:

  • Review recent molecular, biologic, developmental therapeutic, and clinical findings in conventional and variant chondrosarcomas.
  • Highlight advances in classification and therapy for cartilaginous tumors.

Main Methods:

  • Literature review of molecular, biologic, developmental therapeutic, and clinical findings.
  • Analysis of prognostic markers and therapeutic targets.
  • Examination of genetic fusions in extraskeletal myxoid chondrosarcoma.

Main Results:

Related Experiment Videos

  • Newer markers of cell differentiation, activation, genetics, and cell signaling provide prognostic information.
  • Potential therapeutic targets include platelet-derived growth factor receptor, estrogen signaling, and vascular endothelial growth factor-A.
  • Extraskeletal myxoid chondrosarcoma is a unique entity characterized by a CHN/NOR1-EWSR1 fusion gene.
  • Chemotherapy benefit for dedifferentiated chondrosarcomas is questionable; long-term follow-up is crucial for clear cell variants due to late recurrences.

Conclusions:

  • Chondrosarcomas exhibit significant heterogeneity.
  • Advances in molecular diagnostics and developmental therapeutics are crucial for improving classification and therapy.
  • Improved understanding aids both scientists and clinicians in managing these tumors.